×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Loan Against Mutual Fund
Apply Now
Gold Loan
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Vouchers
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Invest in Unlisted Shares
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
#MFSummit2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Budget 2026
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
PF
Forum
Videos
you are here:
Home
News
Price erosion won't impact generic cos in US: Dishman Pharma
Dishman Pharma's Swiss units clear US FDA inspection
Exports to US will continue normally post audit: Dishman Pharma
Not received warning from USFDA on Clovis: Dishman Pharma
Dishman Pharma sees Rs 100 cr debt reduction in FY16
Aim Rs 250 cr sales for Vitamin D biz by FY15 end: Dishman
Margins to pick up in H2, will meet FY15 guidance: Dishman
Margins to scale up to 20% by FY15-end: Dishman Pharma
Dishman Pharma expects earnings to improve in Q3, Q4
Dishman pins hopes on China unit
May surpass FY14 rev guidance by 5%: Dishman Pharma
Dishman Pharma post standalone Q2 PAT at Rs 13.52cr sans Fx
I-T survey for Rs 42cr land deal; will take action: Dishman
Expect to cut debt by Rs 70-80 cr this year: Dishman Pharma
Contract research to boost performance in FY13: Dishman
Dishman Pharma to repay Rs 100cr debt in FY13
Dishman Pharma expects 25% growth in FY13
Better R&D income led to jump in profits: Dishman Pharma
Creapharm buy funded via internal accruals: Dishman Pharma
FY12 profit to be better than FY11: Dishman Pharma
Dishman Pharma eyes over 15% topline growth going forward
Dishman Pharma expects a 15% growth in FY12
Dishman Pharma expects 15% consolidated growth, says CFO
Dishman Pharma eyes 15% topline, bottomline growth in FY12
Dishman Pharma eyes 15% growth in FY12
View More
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio